Amyloid Beta 42 (AB42) is the predominant form of Amyloid Beta found in the brain of patients with Alzheimer’s disease and Down syndrome. Chemically, the main pathogenesis of Alzheimer’s disease is widely believed to be driven by the production and deposition of the Amyloid Beta peptides. PirB (paired immunoglobulin-like receptor B) has been shown to be a receptor for Amyloid Beta oligomers with nanomolar affinity. It also has been shown to induce neuronal death via actions at the p75 neurotrophic receptor. This peptide will impair synaptic plasticity and cause synaptic loss associated with Alzheimer’s disease. Conjugated to Saporin, this could be a tool to help study and model Alzheimer’s disease, Down syndrome, and synaptic plasticity.
Amyloid Beta 42-SAP eliminates cells that express murine PirB (paired immunoglobulin-like receptor B) and p75 receptor expressing cells.
The following control is recommended for validating the specificity of the beta conjugate: Blank-Streptavidin-SAP (Cat. #IT-27B).
This product is being offered as part of our Beta Testing program. It has saporin activity confirmed, peptide sequences published/confirmed, and/or antibody binding specificity published/confirmed. It has not been characterized or reported in scientific literature. The researcher who first publishes data* will receive a $500 credit for use on ATS products.
*Data subject to review by the scientific team at ATS. See complete details here.